JAK2 and neoplasm: Nonetheless, the 50% unresponsive mice group, presumably resistant to momelotinib treatment, that developed tumors showed levels of JAK2/STAT3 activation, c-Kit and Oct3/4 expression that were similar to their paclitaxel+ momelotinib counterparts in Phase 1 which also showed similar tumor burden.